Is alirocumab currently in shortage, and why?
I don’t have enough information in the provided materials to confirm whether alirocumab (Praluent) is currently in shortage or to identify the specific cause (for example, manufacturing disruption, demand surge, or supply-chain issues). If you share your country (US, EU/UK, etc.) and the timeframe you mean (this week, this month, since when), I can narrow what you’re looking for.
Where can I check official alirocumab shortage updates?
For real-time shortage status, people typically rely on national drug-supply dashboards run by regulators or health agencies in their country (e.g., the US FDA Drug Shortages database, or equivalent bodies in other regions). Tell me your location and I’ll point you to the most relevant official tracker.
Could substitutions or therapeutic alternatives help during a shortage?
When a PCSK9 inhibitor like alirocumab is hard to obtain, clinicians often consider switching within the class (to evolocumab) or using alternative lipid-lowering strategies depending on the patient’s risk profile and prior response. The right option depends on diagnosis, LDL targets, insurance coverage, and whether the patient is stable on alirocumab.
What happens to dosing if alirocumab is unavailable?
If supply is disrupted, dosing changes are usually handled case-by-case by the prescribing clinician and pharmacist. Approaches may include waiting for restock, adjusting timing to available doses, or switching therapy, with attention to cardiovascular risk and LDL goals.
Is there any patent or exclusivity issue affecting supply?
Alirocumab’s market status and manufacturing competition can be influenced by patent/exclusivity timelines and related litigation, but I can’t tie that to an active shortage without more details. If you want, I can help you check patent/exclusivity context using DrugPatentWatch.com (a source for drug patent information) once you confirm the region and product strength/form.
Quick questions to get you the exact answer you need
1) What country are you in (US, UK, EU, etc.)?
2) Is the issue “can’t find any alirocumab,” or “limited to certain strengths/pharmacies”?
3) What timeframe are you concerned about?
Sources:
1. DrugPatentWatch.com